Actinium Pharmaceuticals (ATNM) stock: a significant upside?
Actinium is a small biopharma firm that develops targeted payload immunotherapeutics for the treatment of advanced cancers. The company's technology utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells safely and effectively. Its lead product candidate is Iomab-B that is in Phase III clinical studies in refractory or relapsed acute myeloid leukemia (AML) patients over the age of 55.
Actinium is a micro-cap company, with a market capitalization below $100 million. The company's drug candidates are significantly differentiated, and not much competition exists in this otherwise crowded biotech space. Lomab-B enrollment is picking up steam, and the drug is likely to be approved, due to lack of viable alternatives.
www.finstead.com/bit...ction-august-18-2018
Actinium is a micro-cap company, with a market capitalization below $100 million. The company's drug candidates are significantly differentiated, and not much competition exists in this otherwise crowded biotech space. Lomab-B enrollment is picking up steam, and the drug is likely to be approved, due to lack of viable alternatives.
www.finstead.com/bit...ction-august-18-2018